| 25.13 0.39 (1.58%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.8 | 1-year : | 34.8 |
| Resists | First : | 25.51 | Second : | 29.8 |
| Pivot price | 23.93 |
|||
| Supports | First : | 21.98 | Second : | 19.8 |
| MAs | MA(5) : | 24.33 |
MA(20) : | 23.91 |
| MA(100) : | 23.28  |
MA(250) : | 20.87 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 73.4 |
D(3) : | 67.8 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 27.7 | Low : | 12.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MRUS ] has closed below upper band by 2.8%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.48 - 25.58 | 25.58 - 25.69 |
| Low: | 24.03 - 24.13 | 24.13 - 24.25 |
| Close: | 24.93 - 25.1 | 25.1 - 25.3 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Sat, 02 Dec 2023
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress ... - GlobeNewswire
Thu, 30 Nov 2023
Should Biotechnology Stock Merus NV (MRUS) Be in Your Portfolio Thursday? - InvestorsObserver
Sun, 26 Nov 2023
2023-11-26 | NDAQ:MRUS | Press Release | Merus NV - Stockhouse Publishing
Wed, 08 Nov 2023
Is Merus NV (MRUS) a Winner in the Healthcare Sector? - InvestorsObserver
Mon, 23 Oct 2023
Merus' Zeno Interim Data Continues to Demonstrate Robust and ... - Yahoo Finance
Sun, 15 Oct 2023
Merus Announces Business Update Conference Call - October 15 ... - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 83.8 (%) |
| Shares Short | 6,540 (K) |
| Shares Short P.Month | 4,650 (K) |
| EPS | -3.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.8 |
| Profit Margin | 0 % |
| Operating Margin | -347.8 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -51.1 % |
| Qtrly Rev. Growth | 67.5 % |
| Gross Profit (p.s.) | -1.87 |
| Sales Per Share | 0.79 |
| EBITDA (p.s.) | -2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -136 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -6.76 |
| PEG Ratio | 0 |
| Price to Book value | 3.69 |
| Price to Sales | 31.76 |
| Price to Cash Flow | -10.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|